UroGen Pharma
URGN
65 hedge funds and large institutions have $109M invested in UroGen Pharma in 2022 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 12 increasing their positions, 25 reducing their positions, and 25 closing their positions.
3.49% less ownership
Funds ownership: 62.75% → 59.26% (-3.5%)
12% less capital invested
Capital invested by funds: $124M → $109M (-$14.7M)
22% less funds holding
Funds holding: 83 → 65 (-18)
52% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 25
64% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 25
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $1K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$5.78M |
| 2 |
Millennium Management
New York
|
+$3.15M |
| 3 |
LCM
Laurion Capital Management
New York
|
+$2.61M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$1.64M |
| 5 |
Wells Fargo
San Francisco,
California
|
+$939K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$9.34M |
| 2 |
State Street
Boston,
Massachusetts
|
-$2.83M |
| 3 |
ZCA
Zeke Capital Advisors
Berwyn,
Pennsylvania
|
-$1.57M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$1.11M |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$961K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Legal & General Group
London,
United Kingdom
| – | -$86K | -9,857 | Closed |
|
|
AIG
77
American International Group
New York
| – | -$84K | -9,685 | Closed |
|
78
Ohio Public Employees Retirement System (OPERS)
Columbus,
Ohio
| – | -$54K | -6,200 | Closed |
|
|
DA
79
Denali Advisors
San Diego,
California
| – | -$36K | -4,100 | Closed |
|
|
PA
80
Parallel Advisors
San Francisco,
California
| – | -$28K | -3,047 | Closed |
|
|
AB
81
Amalgamated Bank
New York
| – | -$26K | -2,960 | Closed |
|
|
AIP
82
Ameritas Investment Partners
Lincoln,
Nebraska
| – | -$14K | -1,653 | Closed |
|
83
Zurich Cantonal Bank
Zurich,
Switzerland
| – | -$11K | -1,282 | Closed |
|
84
Macquarie Group
Sydney, NSW 2000,
Australia
| – | -$8 | -959 | Closed |
|
|
PFS
85
Prospera Financial Services
Dallas,
Texas
| – | -$3K | -350 | Closed |
|
|
SOW
86
State of Wyoming
Cheyenne,
Wyoming
| – | -$3K | -337 | Closed |
|
87
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| – | -$2K | -253 | Closed |
|
88
Simplex Trading
Chicago,
Illinois
| – | -$1.14K | -166 | -58% |
|
89
Rockefeller Capital Management
New York
| – | +$275 | +40 | New |
|
URGN Hedge Fund Activity: Q2 2022 in Review
65 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q2 2022, worth a combined $109M — down 12% from $124M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of URGN and 9 opened new positions — a net loss of 16 holders — while 25 trimmed existing stakes and 12 added.
The largest buyer was Stonepine Capital Management, adding an estimated $5.78M. The largest seller was BlackRock, cutting an estimated $9.34M.
- 65 institutional investors held UroGen Pharma (URGN) as of Q2 2022, down from 83 in Q1 2022.
- Funds reported $109M of UroGen Pharma stock for Q2 2022, down 12% quarter-over-quarter.
- 9 funds opened new UroGen Pharma positions in Q2 2022 and 25 closed out, a net change of -16 holders.
- The largest UroGen Pharma buyer in Q2 2022 was Stonepine Capital Management, an estimated $5.78M added.
- The largest UroGen Pharma seller in Q2 2022 was BlackRock, an estimated $9.34M sold.
Based on aggregated 13F filings for Q2 2022.